Mifepristone

Generic Name
Mifepristone
Brand Names
Korlym, Mifegymiso
Drug Type
Small Molecule
Chemical Formula
C29H35NO2
CAS Number
84371-65-3
Unique Ingredient Identifier
320T6RNW1F
Background

Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary c...

Indication

For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.

Associated Conditions
Hyperglycemia
Associated Therapies
Medically induced abortion
Clinical Trials
Related News

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

Phase 2
Terminated
Conditions
Cushing's Syndrome
Interventions
Drug: Mifepristone
First Posted Date
2007-01-15
Last Posted Date
2019-10-11
Lead Sponsor
HRA Pharma
Target Recruit Count
18
Registration Number
NCT00422201
Locations
🇮🇹

Universita Degli Studi, Napoli, Italy

🇮🇹

University of Padova, Padova, Italy

🇳🇱

Internal Medicine Endocrinology, Eindhoven, Netherlands

and more 12 locations

Cervical Rippening With Antiprogesterone in Midtrimester Abortions

Phase 4
Completed
Conditions
Abortion, Missed
Interventions
Drug: Mifepristone
First Posted Date
2006-12-12
Last Posted Date
2017-03-01
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
145
Registration Number
NCT00410345
Locations
🇮🇱

Hadassah Medical Organization, Jerusalem, Israel

Mifepristone Versus Laminaria for Cervical Ripening in Midtrimester Induction

Not Applicable
Completed
Conditions
Abortion, Induced
First Posted Date
2006-10-02
Last Posted Date
2023-10-24
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Target Recruit Count
72
Registration Number
NCT00383032
Locations
🇺🇸

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT

Not Applicable
Completed
Conditions
Depression
Interventions
Drug: Placebo Oral Capsule
Drug: Mifepristone
First Posted Date
2006-02-02
Last Posted Date
2017-02-16
Lead Sponsor
Stanford University
Target Recruit Count
11
Registration Number
NCT00285818
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

A Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine Leiomyomas

Phase 2
Terminated
Conditions
Leiomyoma
First Posted Date
2005-09-22
Last Posted Date
2016-04-06
Lead Sponsor
Poitiers University Hospital
Target Recruit Count
20
Registration Number
NCT00219778
Locations
🇫🇷

Poitiers University Hospital, Poitiers, France

A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression

Phase 3
Completed
Conditions
Depressive Disorder, Major
Interventions
Drug: Mifepristone
First Posted Date
2005-09-21
Last Posted Date
2012-02-15
Lead Sponsor
Corcept Therapeutics
Target Recruit Count
87
Registration Number
NCT00208156
Locations
🇺🇸

Claghorn-Lesem Research Clinic, Bellaire, Texas, United States

🇺🇸

New Jersey Medical School - UMDNJ, Newark, New Jersey, United States

🇺🇸

Cnri, Llc, San Diego, California, United States

and more 9 locations

Termination of Pregnancy With Mifepristone and Misoprostol Versus Sulprostone

First Posted Date
2005-09-21
Last Posted Date
2007-10-30
Lead Sponsor
Atrium Medical Center
Registration Number
NCT00206193
Locations
🇳🇱

Atrium Medisch Centrum, Heerlen, Limburg, Netherlands

Mifepristone in Refractory Depression

Not Applicable
Completed
Conditions
Depression
Interventions
Drug: Mifepristone
Drug: Placebo Oral Tablet
First Posted Date
2005-09-16
Last Posted Date
2017-04-05
Lead Sponsor
Stanford University
Target Recruit Count
31
Registration Number
NCT00186056
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: placebo
Drug: Mifepristone
First Posted Date
2005-09-07
Last Posted Date
2012-02-15
Lead Sponsor
Corcept Therapeutics
Target Recruit Count
247
Registration Number
NCT00146523
Locations
🇭🇷

Dubravka Kocijan-Hercigonja M.D., Zagreb, Croatia

🇭🇷

Vera Folnegovic-Smalc M.D./Ph.D., Zagreb, Croatia

🇷🇴

Mihai Dumitru Gheorge, Bucharest, Romania

and more 16 locations

Mifepristone (RU-486) in Androgen Independent Prostate Cancer

First Posted Date
2005-09-01
Last Posted Date
2009-12-09
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
48
Registration Number
NCT00140478
Locations
🇺🇸

Georgetown University, Washington, District of Columbia, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy